Friday, March 8, 2019
Trovagene Inc. (TROV)
Focus on upcoming catalyst, 2018 earnings review and early 2019 developments.
TrovaGene Inc is a US-based life science company which focuses on the development and commercialization of a proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research and medical testing across a variety of clinical disciplines, including oncology and virology.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- Progressing clinical programs. The company continues to focus on
advancement of its clinical programs. We have seen two clinical trials readouts
up to date 1) from Phase 1b/2 acute myeloid leukemia (AML) study-
demonstrating favorable clinical benefit (80% disease control rate) among 12
acute myeloid leukemia (AML) patients and 2) from Phase 1/2 metastatic
castration resistant prostate cancer (mCRPC) program- leading to dosing
adjustments to extend drug exposure and clinical benefit in mCRPC patients. - Upcoming catalysts. We are expecting to see a few key value generating
events 1) further data readouts from Phase 1b/2 acute myeloid leukemia
(AML) program at American Association for Cancer Research (AACR) annual
meeting, 2) data readout f…
Get full report on Channelchek desktop.
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.
